BR9810177A - Composto, formulação farmacêutica, uso de um composto, e, processos para tratamento de uma condição onde a inibição da trombina é requerida e para a preparação de compostos - Google Patents

Composto, formulação farmacêutica, uso de um composto, e, processos para tratamento de uma condição onde a inibição da trombina é requerida e para a preparação de compostos

Info

Publication number
BR9810177A
BR9810177A BR9810177-3A BR9810177A BR9810177A BR 9810177 A BR9810177 A BR 9810177A BR 9810177 A BR9810177 A BR 9810177A BR 9810177 A BR9810177 A BR 9810177A
Authority
BR
Brazil
Prior art keywords
compound
treating
processes
condition
pharmaceutical formulation
Prior art date
Application number
BR9810177-3A
Other languages
English (en)
Inventor
Olle Karlsson
Marcel Linschoten
Nystr M Jan-Erik
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9702378A external-priority patent/SE9702378D0/xx
Priority claimed from SE9801099A external-priority patent/SE9801099D0/xx
Application filed by Astra Ab filed Critical Astra Ab
Publication of BR9810177A publication Critical patent/BR9810177A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"COMPOSTO, FORMULAçãO FARMACêUTICA, USO DE UM COMPOSTO, E, PROCESSOS PARA TRATAMENTO DE UMA CONDIçãO ONDE A INIBIçãO DA TROMBINA é REQUERIDA E PARA A PREPARAçãO DE COMPOSTOS" Forneceu-se compostos da fórmula (I), em que R^ 1^, R~ x~, Y, R^ y^, n e B têm os significados dados na descrição, os quais são utilizáveis como inibidores competitivos das proteases semelhantes à tripsina, tais como a trombina, e em particular no tratamento de condições onde a inibição da trombina é requerida (por exemplo, na trombose) ou como anticoagulantes.
BR9810177-3A 1997-06-19 1998-06-09 Composto, formulação farmacêutica, uso de um composto, e, processos para tratamento de uma condição onde a inibição da trombina é requerida e para a preparação de compostos BR9810177A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9702378A SE9702378D0 (sv) 1997-06-19 1997-06-19 New compounds
SE9801099A SE9801099D0 (sv) 1998-03-30 1998-03-30 New compounds
PCT/SE1998/001103 WO1998057932A1 (en) 1997-06-19 1998-06-09 New amidino derivatives and their use as thrombin inhibitors

Publications (1)

Publication Number Publication Date
BR9810177A true BR9810177A (pt) 2000-08-08

Family

ID=26663014

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9810177-3A BR9810177A (pt) 1997-06-19 1998-06-09 Composto, formulação farmacêutica, uso de um composto, e, processos para tratamento de uma condição onde a inibição da trombina é requerida e para a preparação de compostos

Country Status (20)

Country Link
US (2) US6265397B1 (pt)
EP (1) EP1012140B1 (pt)
JP (2) JP3919236B2 (pt)
KR (1) KR100540413B1 (pt)
CN (1) CN1205187C (pt)
AR (1) AR013084A1 (pt)
AT (1) ATE277902T1 (pt)
AU (1) AU737645C (pt)
BR (1) BR9810177A (pt)
CA (1) CA2294059C (pt)
DE (1) DE69826693T2 (pt)
EE (1) EE9900600A (pt)
IL (1) IL133490A0 (pt)
IS (1) IS5302A (pt)
NO (1) NO315156B1 (pt)
NZ (1) NZ501635A (pt)
PL (1) PL337645A1 (pt)
SK (1) SK167099A3 (pt)
TR (1) TR199903134T2 (pt)
WO (1) WO1998057932A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR013084A1 (es) * 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados
SE9704543D0 (sv) 1997-12-05 1997-12-05 Astra Ab New compounds
SE9804313D0 (sv) * 1998-12-14 1998-12-14 Astra Ab New compounds
DK1150996T3 (da) 1999-01-13 2008-02-11 Astrazeneca Ab Nye amidinobenzylaminderivater og deres anvendelse som thrombin-inhibitorer
AR023510A1 (es) 1999-04-21 2002-09-04 Astrazeneca Ab Un equipo de partes, formulacion farmaceutica y uso de un inhibidor de trombina.
EP1059302A1 (en) * 1999-06-08 2000-12-13 Aventis Pharma Deutschland GmbH Factor VIIa inhibitors
SE0000382D0 (sv) 2000-02-07 2000-02-07 Astrazeneca Ab New process
US6403818B1 (en) 2000-02-28 2002-06-11 Eisai Co., Ltd. Process for producing α-hydroxy-carbonyl compound
SE0001803D0 (sv) * 2000-05-16 2000-05-16 Astrazeneca Ab New compounds i
US6433186B1 (en) 2000-08-16 2002-08-13 Astrazeneca Ab Amidino derivatives and their use as thormbin inhibitors
AR035216A1 (es) * 2000-12-01 2004-05-05 Astrazeneca Ab Derivados de acido mandelico ,derivados farmaceuticamente aceptables, uso de estos derivados para la fabricacion de medicamentos, metodos de tratamiento ,procesos para la preparacion de estos derivados, y compuestos intermediarios
US7129233B2 (en) * 2000-12-01 2006-10-31 Astrazeneca Ab Mandelic acid derivatives and their use as thrombin inhibitors
CA2445591A1 (en) 2001-04-27 2002-11-07 The Procter & Gamble Company Nitrogen heterocyclic compounds and compositions for controlling biofilms
AR034517A1 (es) * 2001-06-21 2004-02-25 Astrazeneca Ab Formulacion farmaceutica
SE0201659D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab Modified release pharmaceutical formulation
SE0201661D0 (sv) 2002-05-31 2002-05-31 Astrazeneca Ab New salts
AU2004233863B2 (en) 2003-04-24 2010-06-17 Incyte Holdings Corporation Aza spiro alkane derivatives as inhibitors of metalloproteases
US7781424B2 (en) * 2003-05-27 2010-08-24 Astrazeneca Ab Modified release pharmaceutical formulation
WO2005044814A1 (en) * 2003-11-07 2005-05-19 F. Hoffmann-La Roche Ag BENZO [b][1,4] DIOXEPINE DERIVATIVES
US7524354B2 (en) * 2005-07-07 2009-04-28 Research Foundation Of State University Of New York Controlled synthesis of highly monodispersed gold nanoparticles
UA95788C2 (en) 2005-12-15 2011-09-12 Ф. Хоффманн-Ля Рош Аг Fused pyrrole derivatives
TW200827336A (en) * 2006-12-06 2008-07-01 Astrazeneca Ab New crystalline forms
US20090061000A1 (en) * 2007-08-31 2009-03-05 Astrazeneca Ab Pharmaceutical formulation use 030
DE102008007440A1 (de) * 2008-02-01 2009-08-13 Dritte Patentportfolio Beteiligungsgesellschaft Mbh & Co.Kg Aminosäurederivate als Arzneistoffe
EA018502B1 (ru) * 2008-06-23 2013-08-30 Астразенека Аб Новые гетероциклические карбоксамиды и фармацевтические композиции, содержащие их
CN104327029A (zh) * 2014-09-21 2015-02-04 湖南华腾制药有限公司 一种含氧杂环化合物的制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU178398B (en) 1979-06-12 1982-04-28 Gyogyszerkutato Intezet Process for producing new agmatine derivatives of activity against haemagglutination
HU192646B (en) 1984-12-21 1987-06-29 Gyogyszerkutato Intezet Process for preparing new n-alkyl-peptide aldehydes
ZA86746B (en) 1985-02-04 1986-09-24 Merrell Dow Pharma Novel peptidase inhibitors
US5187157A (en) 1987-06-05 1993-02-16 Du Pont Merck Pharmaceutical Company Peptide boronic acid inhibitors of trypsin-like proteases
EP0362002B1 (en) 1988-09-01 1995-07-26 Merrell Dow Pharmaceuticals Inc. HIV protease inhibitors
ZA897514B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
TW201303B (pt) 1990-07-05 1993-03-01 Hoffmann La Roche
CA2075154A1 (en) 1991-08-06 1993-02-07 Neelakantan Balasubramanian Peptide aldehydes as antithrombotic agents
SE9102462D0 (sv) 1991-08-28 1991-08-28 Astra Ab New isosteric peptides
NZ245039A (en) 1991-11-12 1994-12-22 Lilly Co Eli N-phenylalanyl and n-phenylglycyl derivatives of the dipeptide of l-azetidine-2-carboxylic acid and l-arginine aldehyde; anti-blood clotting compositions
SE9103612D0 (sv) 1991-12-04 1991-12-04 Astra Ab New peptide derivatives
ES2110599T3 (es) 1992-03-04 1998-02-16 Gyogyszerkutato Intezet Nuevos derivados de peptidos anticoagulantes y composiciones farmaceuticas que contienen los mismos, asi como un proceso para su preparacion.
TW223629B (pt) 1992-03-06 1994-05-11 Hoffmann La Roche
US5583146A (en) 1992-12-02 1996-12-10 Bristol-Myers Squibb Company Heterocyclic thrombin inhibitors
AU675981B2 (en) 1992-12-02 1997-02-27 Bristol-Myers Squibb Company Guanidinyl-substituted heterocyclic thrombin inhibitors
JPH06340619A (ja) 1993-05-03 1994-12-13 Bristol Myers Squibb Co グアニジニルまたはアミジニル置換メチルアミノ複素環トロンビン抑制剤
US5780631A (en) 1993-06-03 1998-07-14 Astra Aktiebolag Starting materials in the synthesis of thrombin and kininogenase inhibitors
SE9301916D0 (sv) * 1993-06-03 1993-06-03 Ab Astra New peptides derivatives
EP0648780A1 (en) 1993-08-26 1995-04-19 Bristol-Myers Squibb Company Heterocyclic thrombin inhibitors
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
AU1025795A (en) 1994-01-27 1995-08-03 Mitsubishi Chemical Corporation Prolineamide derivatives
IL112795A (en) 1994-03-04 2001-01-28 Astrazeneca Ab Derivatives of peptides as antithrombotic drugs, their preparation, and pharmaceutical preparations containing them
US5707966A (en) 1994-03-04 1998-01-13 Eli Lilly And Company Antithrombotic agents
US5705487A (en) 1994-03-04 1998-01-06 Eli Lilly And Company Antithrombotic agents
US5726159A (en) 1994-03-04 1998-03-10 Eli Lilly And Company Antithrombotic agents
US5561146A (en) 1994-06-10 1996-10-01 Bristol-Myers Squibb Company Modified guanidino and amidino thrombin inhibitors
DE4421052A1 (de) 1994-06-17 1995-12-21 Basf Ag Neue Thrombininhibitoren, ihre Herstellung und Verwendung
US5510369A (en) 1994-07-22 1996-04-23 Merck & Co., Inc. Pyrrolidine thrombin inhibitors
DE4443390A1 (de) 1994-12-06 1996-06-13 Basf Ag Neue dipeptidische p-Amidinobenzylamide mit N-terminalen Sulfonyl- bzw. Aminosulfonylresten
CN1173872A (zh) 1995-02-10 1998-02-18 巴斯福股份公司 凝血酶抑制剂
MX9706069A (es) 1995-02-17 1997-10-31 Basf Ag Nuevos inhibidores de la trombina.
US5710130A (en) 1995-02-27 1998-01-20 Eli Lilly And Company Antithrombotic agents
US5914319A (en) 1995-02-27 1999-06-22 Eli Lilly And Company Antithrombotic agents
AU698911B2 (en) 1995-04-04 1998-11-12 Merck & Co., Inc. Thrombin inhibitors
US5629324A (en) 1995-04-10 1997-05-13 Merck & Co., Inc. Thrombin inhibitors
SA96170106A (ar) 1995-07-06 2005-12-03 أسترا أكتيبولاج مشتقات حامض أميني جديدة
TWI238827B (en) 1995-12-21 2005-09-01 Astrazeneca Ab Prodrugs of thrombin inhibitors
AU1990197A (en) 1996-03-12 1997-10-01 Bristol-Myers Squibb Company Carbamyl guanidine and amidine prodrugs
JPH1095898A (ja) 1996-09-25 1998-04-14 Sumitomo Bakelite Co Ltd 難燃性樹脂組成物およびこれを用いた積層板
SE9602263D0 (sv) 1996-06-07 1996-06-07 Astra Ab New amino acid derivatives
SE9602646D0 (sv) 1996-07-04 1996-07-04 Astra Ab Pharmaceutically-useful compounds
DE19632772A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Benzamidine
DE19632773A1 (de) 1996-08-14 1998-02-19 Basf Ag Neue Thrombininhibitoren
AR013084A1 (es) * 1997-06-19 2000-12-13 Astrazeneca Ab Derivados de amidino utiles como inhibidores de la trombina, composicion farmaceutica, utilizacion de dichos compuestos para la preparacion demedicamentos y proceso para la preparacion de los compuestos mencionados

Also Published As

Publication number Publication date
EP1012140A1 (en) 2000-06-28
PL337645A1 (en) 2000-08-28
NZ501635A (en) 2001-09-28
TR199903134T2 (xx) 2000-07-21
CN1205187C (zh) 2005-06-08
IS5302A (is) 1999-12-15
NO996313L (no) 2000-02-21
AU737645C (en) 2002-03-21
US6265397B1 (en) 2001-07-24
US6576657B2 (en) 2003-06-10
DE69826693D1 (de) 2004-11-04
NO996313D0 (no) 1999-12-17
DE69826693T2 (de) 2006-02-16
JP2006321807A (ja) 2006-11-30
KR100540413B1 (ko) 2006-01-12
EE9900600A (et) 2000-08-15
JP2002503256A (ja) 2002-01-29
ATE277902T1 (de) 2004-10-15
AR013084A1 (es) 2000-12-13
AU737645B2 (en) 2001-08-23
EP1012140B1 (en) 2004-09-29
US20020022612A1 (en) 2002-02-21
KR20010013982A (ko) 2001-02-26
WO1998057932A1 (en) 1998-12-23
SK167099A3 (en) 2000-06-12
IL133490A0 (en) 2001-04-30
CA2294059A1 (en) 1998-12-23
CN1266427A (zh) 2000-09-13
AU7946198A (en) 1999-01-04
CA2294059C (en) 2008-12-09
JP3919236B2 (ja) 2007-05-23
NO315156B1 (no) 2003-07-21

Similar Documents

Publication Publication Date Title
BR9810177A (pt) Composto, formulação farmacêutica, uso de um composto, e, processos para tratamento de uma condição onde a inibição da trombina é requerida e para a preparação de compostos
BR0115861A (pt) Composto, derivado farmaceuticamente aceitável de um composto, formulação farmacêutica, uso de um composto, métodos de tratamento de uma condição onde a inibição da trombina é requerida e de uma condição onde a terapia anticoagulante é indicada, e, processo para a preparação de um composto
BR9813410A (pt) Composto, formulação farmacêutica, uso de um composto, e, processos de tratamento de uma condição, em que a inibição de trombina é requerida ou desejada, e para a preparação de um composto.
BR0007453A (pt) Composto, formulação farmacêutica, uso de umcomposto, método de tratamento de uma condiçãoonde a inibição da trombina é requerida e,processo de preparação de um composto
AR007614A1 (es) Compuesto derivado de amidino, formulacion farmaceutica que lo incluye, metodos para la elaboracion de medicamentos que contienen a dicho compuesto, yproceso para la preparacion de dicho compuesto.
BR9911488A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou de profilaxia de doenças inflamatórias, e para a preparação de um composto
BR0210358A (pt) Inibidores da protease de hiv, composições contendo os mesmos, seus usos farmacêuticos e materiais para sua sìntese
BRPI0312464B8 (pt) compostos inibidores de tirosina quinases, composições farmacêuticas compreendendo os mesmos, processos para fabricação e usos dos mesmos
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
BR9714082A (pt) Composto, uso do mesmo, composição farmacêutica, e, processos para tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto.
FI942423A0 (fi) Sakkariinijohdannisia proteolyyttisen entsyymin inhibiittoreina
BR9907886A (pt) Composto, uso do mesmo, composição farmacêutica, e, processo de tratamento ou profilaxia de doenças inflamatórias, por exemplo asma ou copd.
TR199902606T2 (xx) Farnesil transferaz� engelleyici kinazolinonlar.
BR0014384A (pt) Compostos para o tratamento da isquémia
NO992821L (no) Ketobenzamider som calpain-inhibitorer
BR9907270A (pt) Composto, composição farmacêutica, uso de um composto, e, processos para tratamento ou profilaxia de doenças inflamatórias, por exemplo, asma ou copd, e para a preparação de um composto
BR9713465A (pt) Inibidores metalotprotease de amina cìclica sibstituìda
BR9811099A (pt) Inibidores de urocinase
SE9602263D0 (sv) New amino acid derivatives
AR024138A1 (es) Inhibidores de la proliferacion celular
NO983688L (no) Serin-protease-inhibitorer
BR0014804A (pt) Composto, formulação farmacêutica, uso de um composto, método de profilaxia ou tratamento de uma arritmia, e, processo para a preparação de um composto
BR0315143A (pt) Composto, processo para a preparação dos (r) e (s) - enanciÈmeros individuais ou misturas de enanciÈmeros e sais farmaceuticamente aceitáveis de um composto, composição farmacêutica, e, uso de um composto
BR9910573A (pt) Compostos antipicornavirais, preparação e uso dos mesmos
BR9916255A (pt) Composto, composição farmacêutica, uso de um composto, e, métodos de tratamento de uma condição em que se requer inibição de trombina e para a preparação de compostos

Legal Events

Date Code Title Description
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: ALTERADA DE INT.CL: A61K 31/401, A61K 31/4025, A61K 31/435, A61K 31/397, A61P 7/02

Ipc: C07D 207/16 (2008.04), A61K 31/40 (2008.04)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements